Inflammatory bowel diseases
-
Inflamm. Bowel Dis. · Apr 2011
Comparative StudyAngiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease.
Angiogenesis is a complex process, involving a great number of mediators. It is implicated in the pathogenesis of numerous diseases, holding a critical role in inflammatory bowel disease (IBD). The objective of this study was to assess serum levels of angiogenin, angiopoietin-1, angiopoietin-2, and endostatin in IBD patients. ⋯ Elevated serum angiogenin and angiopoietin-2 levels and lower serum angiopoietin-1 levels were shown in IBD patients, as well as a different pattern of angiogenic factor alterations related to location, treatment, smoking habits and gender.
-
Inflamm. Bowel Dis. · Sep 2010
High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study.
To date, there have been no population-based epidemiological studies published from Australia concerning the incidence of inflammatory bowel disease (IBD). Our hypothesis was that the incidence of IBD in Australia is at least as high as other industrialized countries, given similar genetic and environmental risk factors. ⋯ This is the first prospective, Australian population-based IBD incidence study. The incidence rates are among the highest reported in the literature of IBD.
-
Inflamm. Bowel Dis. · Jul 2010
Randomized Controlled Trial Multicenter StudyRandomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD). We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD. ⋯ Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.